Loading...
•
Mar 31, 2025
Gossamer Bio Q1 2025 Earnings Report
Gossamer Bio reported a narrowed net loss and recorded $9.9 million in collaboration revenue in Q1 2025.
Key Takeaways
In Q1 2025, Gossamer Bio reported $9.9 million in collaboration revenue and a net loss of $36.6 million, while continuing to advance its registrational studies for seralutinib. The company closed new patient screening for its Phase 3 PROSERA Study and maintains a strong cash position to fund operations into the first half of 2027.
Reported $9.9 million in collaboration revenue, including $6.6 million from cost reimbursements.
Net loss decreased to $36.6 million from $41.9 million in Q1 2024.
Cash and marketable securities totaled $257.9 million, expected to fund operations into H1 2027.
Patient screening closed for Phase 3 PROSERA Study; topline data expected in February 2026.
Revenue by Segment
Forward Guidance
Gossamer expects to complete enrollment in the Phase 3 PROSERA Study in June 2025 and initiate the SERANATA Study in Q4 2025, while maintaining sufficient funding into the first half of 2027.
Positive Outlook
- PROSERA Phase 3 patient screening closed; full enrollment expected in June 2025.
- Topline data from PROSERA Phase 3 study anticipated in February 2026.
- SERANATA Phase 3 study site activations planned for Q4 2025.
- Collaboration with Chiesi advancing seralutinib development globally.
- Sufficient cash runway projected through H1 2027.
Challenges Ahead
- Ongoing operating losses driven by R&D and G&A expenses.
- Total liabilities exceed total assets by $6.25 million.
- Accumulated deficit surpassed $1.3 billion.
- Continued reliance on successful outcomes from seralutinib trials.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...